Senior Associate, Pivotal bioVenture Partners (China)
Kai Chen is a Senior Associate with Pivotal bioVenture Partners China. Prior to joining Pivotal China, Kai was an Associate Director at CStone Pharmaceutical, in charge of Commercial Strategy and New Product Planning. He supported the entire process of commercial launch of two precision oncology products (Ayvakit, Gavreto) and the CStone-Pfizer strategic partnership deal. Prior to CStone, Kai was a Consultant at BCG Greater China Office focusing on healthcare. He has also worked as a Business Development Associate at Simcere Pharmaceuticals US. Kai received his Ph.D. in Chemistry from the University of Chicago (advisor: Prof. Chuan He) and his B.S. in Chemical Biology from Tsinghua University.
Mr. Bisgaard joined Nan Fung and Pivotal Life Sciences in 2017. He was previously a Senior Partner at Novo Ventures (US) Inc. since 2009. As part of Novo’s senior team, he was responsible for Novo Ventures’ overall investment and portfolio strategy as well as the ongoing development of the Novo Ventures team in the US. Prior to that, Mr. Bisgaard was with Novo A/S since 2001 in Denmark. He has both investment and board experience from a large number of private and public US life sciences companies. Prior to joining Novo A/S, Peter was with McKinsey & Co. as a general consultant and as a specialist within the Scandinavian Corporate Finance and Strategy Group. He was part of the strategic and financial advisory teams in multiple large Private Equity and Corporate M&A transactions and strategy projects across industry sectors. Mr. Bisgaard obtained an M.Sc. in Engineering in 1998 from the Technical University of Denmark and was awarded a post-graduate degree in Mathematical Modelling in Economics by the European Consortium for Mathematics in the Industry.
Investment Director – Pivotal Growth
Bibhash is a Partner with Pivotal CNS. Prior to joining the NFLS platform of funds, he was a Principal at NEA where he acquired investing, portfolio management and board leadership experience in a number of private and public biotech companies across various stages, geographies and therapeutic areas. Prior to that, he worked in BD and Corporate Strategy at Astra Zeneca and before that, at Johnson & Johnson. In those roles, he led a number of transactions in pre-clinical and clinical stage assets.
Bibhash did his PhD research on retinal degeneration from Baylor College of Medicine Houston USA, has a Masters in Neuroscience from Max Planck Research School in Germany and an undergrad degree in biomedical sciences from India.
Zhilei joined PivotalChina as Executive director in 2021. Prior to that, he was Executive Director in Epiphron Capital and Vice President in Cathay Capital Private Equity focusing on healthcare investment in Shanghai. Before started his investment professional career, Zhilei was with Sanofi and Abbott (Abbvie) in different roles of Medical Affairs, Product Launch, and Business Strategy and Development. He practiced as a neurosurgeon in Huashan Hospital affiliated to Fudan University after graduation.
Zhilei received his Doctor of Medicine and second bachelor of Economics from Fudan University. He also holds an MBA from CEIBS and MPH from the Johns Hopkins University Bloomberg School of Public Health.
Melissa joined Pivotal in 2018. She assists with the administration and support for the office. Prior to joining Pivotal, she has worked as an Executive Assistant supporting C-level executives in venture capital, tech and real estate investment. Melissa studied at San Francisco State University and majored in Business Administration.